Aktiia, the Series A Swiss startup transforming Blood Pressure monitoring and management, backed by Khosla Ventures, Red Alpine, Molten Ventures, Translink, Verve and 415 Capital, announces the appointment of U.S.-based industry veteran, Raghav ‘Rags’ Gupta, as its new CEO and a member of the Board of Directors. Since its commercial launch in 2021, Aktiia has amassed the largest longitudinal BP dataset of its kind, with over 11 B optical signals and 300 million cardiovascular data points from over 80,000 users. This dataset serves as the foundation for Aktiia’s AI-driven BP Intelligence Platform, which comprises BP measurement, management, and novel research insights.
A seasoned and entrepreneurial technology operator with a track record of growth and commercialization, Rags brings a wealth of experience across consumer, enterprise and deep tech domains. Rags has operated at the intersection of technology and market inflections for most of his career, from the early days of the Web to cloud and SaaS at Brightcove, Videoplaza and Ooyala, to sensing and deep tech, more recently, at Humatics, Butlr, and as an Operating Partner at Hyperplane.
“Aktiia’s mission to reduce the impact of blood pressure on global health is deeply personal. Add to this the novel technology that’s already achieved product market fit and improved patient outcomes, the unique dataset, and the talented, dedicated team, and it makes for a once-in-career opportunity. I’m thrilled to join at such an inflection point in the business,” said Rags Gupta. “It’s time to scale.”
Also Read: Komodo Health Appoints Miles Ennis as Chief Revenue Officer
Aktiia’s CE-marked continuous blood pressure monitor is currently available in seven European markets. Earlier this year, Aktiia received CE approval for its next-generation CALFREE(tm) technology, which utilizes optical sensors that do not require calibration with a traditional cuff. This significantly improves user convenience and adaptability for various third-party devices, while still meeting the stringent BP accuracy and precision thresholds to be medically valid. Additional regulatory submissions are underway in markets, including the U.S.
Built on 20+ years of research, Aktiia’s technology provides unparalleled innovation and ease in blood pressure data collection and machine learning modelling, offering personalized, continuous, and medical-grade blood pressure and heart rate data. Aktiia empowers people, researchers, and clinicians with unique blood pressure data, paving the way for novel understanding and personalized patient care of hypertension.
“Rags’ strategic vision, entrepreneurial track record and ability to operate across cultures and domains stood out to us during our search process, and we’re thrilled to have him join at an inflection point for our business,” said Daniel Graf, President and Board member.
“From the time we spent together, it was clear that Rags had the strategic insight, operational experience and cultural fluency to be our next CEO,” said Aktiia co-founder Mattia Bertschi, who will remain as COO. “We are proud to have him on board as our recent regulatory wins, ongoing research, and real-world adoption drive the next phase of Aktiia’s growth.”
Source: PRNewswire